about
Antibody and cytokine-associated immune responses to S. equi antigens entrapped in PLA nanospheres.Nanocarriers for pulmonary administration of peptides and therapeutic proteins.Biodistribution of lipid nanoparticles: a comparative study of pulmonary versus intravenous administration in rats.Immune system targeting by biodegradable nanoparticles for cancer vaccines.Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases.Preclinical development of siRNA therapeutics: towards the match between fundamental science and engineered systems.Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance.Looking out for cancer stem cells' properties: the value-driving role of CD44 for personalized medicines.Implications of Akt2/Twist crosstalk on breast cancer metastatic outcome.Cancer stem cells and personalized cancer nanomedicine.Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles.Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells.Brain metastasization of breast cancer.In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model.Experimental design towards an optimal lipid nanosystem: a new opportunity for paclitaxel-based therapeutics.Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect.Solid state formulations composed by amphiphilic polymers for delivery of proteins: characterization and stability.Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles.Toxicology and Biodistribution: The Clinical Value of Animal Biodistribution Studies.Rhenium and technetium tricarbonyl complexes anchored by pyrazole-based tripods: novel lead structures for the design of myocardial imaging agentsLymphatic uptake of lipid nanoparticles following endotracheal administration
P50
Q30378025-12FCEE9A-2078-4AFB-9369-4418EC451BF9Q37823598-1962A57B-EEAE-446C-B8C3-326B41A9FE1CQ37978897-07F3F25C-0B1D-4BC8-9486-43AE4FD13CD5Q38092551-D2F9CDDE-A83D-400C-8872-DF7AB2461FC0Q38128069-CF71B186-5AFD-453B-B5B2-BF4733040EE6Q38170904-E95CBDFB-1BD4-4C3E-A9D3-566B9AE57D31Q38235651-582218F2-26D0-4BFA-9D8E-C2325D8348C5Q38267006-53687A86-E21D-4E83-823B-FBEE73C88642Q38542008-4DD52F55-5D51-4B90-8587-38E07368E999Q38702970-2CB2278C-4DF8-4FCE-8A9A-DD8158BDCCB4Q38733200-A350BC1C-6A29-4D4F-A60D-B7EAEE22EC50Q38846958-1C4030ED-FAED-4D9C-8B2F-EBC57BDC3AF4Q38877631-6E869B01-F2B4-4742-9995-1C50CD074A42Q38931309-0A4B8D3D-EF12-4672-B03C-B9FCA48DC966Q39175779-0C52C067-2DF1-40E4-AA24-11CF08B3559CQ39420800-DE7F8E7F-D111-4B8C-B535-39D16B8DA600Q47943533-FE2CDBD4-7827-40C7-AA0E-5A56E8E31456Q47989300-3ABBDB3C-D2D0-4467-82D1-D33F7FAC140CQ52654942-76EDB1EC-2432-415A-8303-5854453A3870Q59166760-073DAAF4-15E2-46DD-AB19-CBD2D6539FBDQ59166767-8181A6EF-B901-4729-8639-880B67FC5BB7
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mafalda Videira
@ast
Mafalda Videira
@en
Mafalda Videira
@es
Mafalda Videira
@nl
Mafalda Videira
@sl
type
label
Mafalda Videira
@ast
Mafalda Videira
@en
Mafalda Videira
@es
Mafalda Videira
@nl
Mafalda Videira
@sl
prefLabel
Mafalda Videira
@ast
Mafalda Videira
@en
Mafalda Videira
@es
Mafalda Videira
@nl
Mafalda Videira
@sl
P106
P1153
24286617000
P21
P31
P496
0000-0003-4184-3963